Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

Novartis is committed to improving access to its RLTs, Pluvicto and Lutathera ® (INN: lutetium (177 Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) by adding more treatment sites in closer ...

Novartis is investigating Pluvicto in earlier stages of disease, including metastatic hormone-sensitive prostate cancer (PSMAddition, NCT04720157) and oligometastatic prostate cancer (PSMA-DC ...

Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...

The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Basel, January 5, 2024— Novartis announced today that it has received approval from the US Food and Drug Administration for commercial manufacturing of Pluvicto TM at its new large-scale, state ...

Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.

Q2 2025 Earnings Call Transcript July 21, 2025 Operator: Good morning and good afternoon, and welcome to the Novartis Q2 2025 ...

Novartis AG (NVS) reports robust sales and income growth, announces a $10 billion share buyback, and navigates competitive ...

Novartis Pharmaceuticals Canada said it is “extremely disappointed” that negotiations for Pluvicto, a treatment for patients with progressive PSMA-positive metastatic castration-resistant ...